Liquid Oncology Dosage Form for Flexible Pediatric Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosage forms for oncological active ingredients, such as capecitabine, raloxifene, and letrozole, do not allow for flexible dosing, particularly for pediatric and geriatric patients, as they are often fixed in solid forms that may not accommodate individual needs, and there is a need for formulations that can be easily titrated and administered in liquid forms.
Innovation Solution
Development of liquid oral solutions, suspensions, and granules containing oncological active ingredients, including capecitabine, raloxifene, and letrozole, with specific compositions that include preservatives, buffers, sweeteners, solvents, flavorings, and chelating agents, allowing for flexible dosing and improved administration methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If solid dosage forms are used for oncological active ingredients, then manufacturing and storage are simplified, but flexible dosing and titration capability are lost
Solution Approach 1:
The patent transforms the dosage form from solid to liquid state, fundamentally changing the physical parameter of the formulation. This enables flexible dosing by allowing the liquid to be divided into variable volumes, while maintaining manufacturing simplicity through established liquid formulation techniques and apheresis-based production methods.
2Adaptability or versatility
If liquid oral solutions are developed for flexible dosing, then dosing flexibility is improved, but formulation complexity increases
Solution Approach 1:
The patent extracts the active pharmaceutical ingredient from its traditional solid dosage form and dissolves it in appropriate liquid vehicles. This separation allows the active ingredient to be delivered in a flexible liquid medium while using standard excipients and formulation techniques, thereby achieving dosing flexibility without excessive complexity.
3Stability of the object's composition
If solid dosage forms are used, then formulation stability is maintained, but ease of administration and patient compliance deteriorate
Solution Approach 1:
The patent changes the physical state parameter from solid to liquid, which inherently improves ease of administration by eliminating the need for crushing, splitting, or swallowing large tablets. The liquid formulation can be easily measured, administered, and adjusted for different patient needs while maintaining stability through controlled formulation conditions.
Data Source
AI summary
The present invention provides for a dosage form (e.g., liquid oral solution, liquid oral suspension, solid oral bead, granules, etc.) that contains one or more oncological active ingredients, methods of administering the same, and methods of manufacturing the same.